Richard Dodd, MD
Endocrinology, Diabetes & Metabolism · Asheville, NCNPI 1427110378
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $498,146 of the $526,036 with a category attached, or 94.7%. 35 manufacturers reported payments, led by Bayer at 29.5% of the total. Reporting peaked in 2019 at $163,449 and has fallen 86.2% since, to $22,599 in 2025. Among endocrinology, diabetes & metabolism clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 934 payments — averaging $563.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$155K
- Johnson & Johnson$102K
- Sanofi-aventis U.S. LLC$67K
- AstraZeneca$67K
- Lilly USA, LLC$63K
- Boehringer Ingelheim$60K
- plus $12K from 29 others
What the payments were for
- Consulting fees$4,7041%
- Speaking & faculty fees$498,14695%
- Travel & lodging$11,0152%
- Food & beverage$12,1362%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 157 | $155,002 |
| Johnson & Johnson | 173 | $101,673 |
| Sanofi-aventis U.S. LLC | 86 | $67,208 |
| AstraZeneca(2 entities) | 90 | $66,836 |
| Lilly USA, LLC | 141 | $63,011 |
| Boehringer Ingelheim | 118 | $60,157 |
| Tandem Diabetes Care, Inc. | 20 | $6,271 |
| Esperion Therapeutics, Inc. | 10 | $3,082 |
| Medtronic(2 entities) | 17 | $490 |
| Novo Nordisk | 21 | $360 |
| Amgen(2 entities) | 17 | $274 |
| Insulet Corporation | 9 | $245 |
| AbbVie | 11 | $212 |
| Dexcom, Inc. | 10 | $209 |
| Abbott | 9 | $181 |
| GSK | 8 | $159 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $97 |
| Corcept Therapeutics | 6 | $84 |
| Otsuka America Pharmaceutical, Inc. | 4 | $75 |
| Ascendis Pharma Endocrinology Inc | 3 | $60 |
| Exact Sciences | 3 | $47 |
| Astellas Pharma US Inc | 2 | $37 |
| Antares Pharma, Inc. | 2 | $35 |
| Gilead | 1 | $27 |
| IBSA Pharma Inc. | 1 | $23 |
| Averitas Pharma Inc. | 1 | $23 |
| Radius Health, Inc. | 1 | $22 |
| Cequr Corporation | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Nevro Corp. | 1 | $19 |
| Novartis | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Lifescan, Inc. | 1 | $15 |
| Merck | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$152,103
- JARDIANCE$120,509
- INVOKANA$71,621
- FARXIGA$64,959
- TOUJEO$32,258
- SOLIQUA 100/33$31,180
- XARELTO$27,674
- t:slim X2 insulin pump$5,500
- NEXLETOL$2,860
- NEXLIZET$2,860
- DISEASE STATE$2,530
- t-slim insulin pump$750
How this compares
$526,036 in reported general payments places this provider in the 95th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 455 | $386,400 |
| KerendiaFinerenone | 272 | $267,848 |
| MounjaroTirzepatide | 149 | $204,282 |
| OzempicSemaglutide | 119 | $141,401 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 94 | $101,099 |
| ProliaDenosumab | 48 | $83,044 |
| TrulicityDulaglutide | 39 | $48,697 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 58 | $45,788 |
| InvokanaCanagliflozin | 34 | $39,931 |
| TymlosAbaloparatide | 13 | $34,114 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 32 | $28,878 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $25,448 |
| FarxigaDapagliflozin Propanediol | 27 | $23,911 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 40 | $15,129 |
| SynjardyEmpagliflozin/Metformin Hcl | 14 | $14,968 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Tradjenta | $60,157 | $440,387515 claims |
| BayerKerendia | $155,002 | $267,848272 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $63,011 | $257,244203 claims |
| Novo NordiskOzempic | $360 | $141,401119 claims |
| AmgenProlia | $274 | $83,04448 claims |
| Johnson & JohnsonInvokana, Xarelto, Invokamet | $101,673 | $64,30267 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $67,208 | $45,78858 claims |
| Radius Health, Inc.Tymlos | $22 | $34,11413 claims |
| AstraZenecaFarxiga | $66,836 | $23,91127 claims |
| MerckJanuvia | $15 | $10,84215 claims |
| Esperion Therapeutics, Inc.Nexletol | $3,082 | $10,72017 claims |
| AbbVieSynthroid | $212 | $7,85871 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
Other endocrinology, diabetes & metabolism in Asheville
- Wendy LaneAsheville$487K
- Victor MarlarAsheville$483K
- Lauren BernsteinAsheville$307K
- Stephen WeinribAsheville$11K
- Hilary ThomasAsheville$10K
- Mark WarrenGreenville$915K
- Thomas OconnellBurlington$805K
- Corey BerlinRaleigh$742K
- Michael FavoritoWilmington$723K
- Stephen SouthGreensboro$624K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.